title: Current and ongoing progress in the therapy for resectable esophageal cancer.
abstract: There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.
authors.affiliation: Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA. cthomas@ctrc.net
authors.forename: C R
authors.initials: CR
authors.lastname: Thomas
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000601:surgery; D004938:Esophageal Neoplasms / Q000601:surgery*; D006801:Humans; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome